Aphria (NASDAQ:APHA) posted its earnings results on Wednesday. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.39), Briefing.com reports. Aphria had a negative return on equity of 2.23% and a negative net margin of 18.30%. The firm had revenue of $160.50 million for the quarter, compared to analyst estimates of $153.75 million. During the same period in the prior year, the business posted ($0.03) EPS. The firm’s quarterly revenue was up 33.1% compared to the same quarter last year.
NASDAQ:APHA opened at $12.42 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.30 and a current ratio of 5.37. The firm’s fifty day simple moving average is $7.62 and its 200 day simple moving average is $6.45. Aphria has a twelve month low of $1.95 and a twelve month high of $14.01.
A number of equities analysts have issued reports on the company. CIBC increased their price target on Aphria from $12.50 to $18.00 and gave the stock an “outperform” rating in a report on Friday. Alliance Global Partners increased their price target on Aphria from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday. Stifel Nicolaus downgraded Aphria from a “buy” rating to a “hold” rating in a research report on Thursday, December 17th. Canaccord Genuity raised Aphria from a “hold” rating to a “speculative buy” rating and raised their price objective for the company from $11.00 to $17.50 in a report on Friday. Finally, BMO Capital Markets boosted their target price on Aphria from $7.00 to $15.00 and gave the company a “market perform” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $14.23.
Aphria Inc cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands.
Featured Story: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.